ATAI Life Sciences
ATAI Life Sciences
ATAI
NASDAQ
1.30
USD
9.24%
About
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries.
Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 550.6K |
| Three Month Average Volume | 16.0M |
| High Low | |
| Fifty-Two Week High | 2.85 USD |
| Fifty-Two Week Low | 1.025 USD |
| Fifty-Two Week High Date | 04 Apr 2024 |
| Fifty-Two Week Low Date | 01 Dec 2023 |
| Price and Volume | |
| Current Price | 1.3 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.47% |
| Thirteen Week Relative Price Change | -22.63% |
| Twenty-Six Week Relative Price Change | -44.49% |
| Fifty-Two Week Relative Price Change | -32.19% |
| Year-to-Date Relative Price Change | -22.14% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -17.20% |
| Twenty-Six Week Price Change | -38.97% |
| Five Day Price Change | -0.76% |
| Fifty-Two Week Price Change | -15.03% |
| Year-to-Date Price Change | -7.80% |
| Month-to-Date Price Change | -16.13% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.46339 USD |
| Book Value Per Share (Most Recent Quarter) | 1.0007 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.46339 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.0007 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.66107 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00198 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00227 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.25325 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.38519 USD |
| Normalized (Last Fiscal Year) | -0.24935 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.25325 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.35037 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.25325 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.38519 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.07969 USD |
| Cash Per Share (Most Recent Quarter) | 0.52658 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.25173 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.3464 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.47664 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -20,957 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -15,140.48% |
| Pretax Margin (Last Fiscal Year) | -12,511.46% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -40,261.79% |
| Operating Margin (Trailing Twelve Months) | -29,407.41% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -12,835.03% |
| Net Profit Margin (Trailing Twelve Months) | -15,320.63% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 58.72% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 39.48% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -68.48% |
| EPS Change (Trailing Twelve Months) | 58.35% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -69,791,000 |
| Net Debt (Last Fiscal Year) | -161,380,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 693 |
| Price to Sales (Trailing Twelve Months) | 576 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 7 |
| Long Term Debt to Equity (Most Recent Quarter) | 11 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -84,707,000 |
| Free Cash Flow (Trailing Twelve Months) | -79,217,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -74 |
| Net Interest Coverage (Trailing Twelve Months) | -91 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 7 |
| Total Debt to Equity (Most Recent Quarter) | 11 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -13.46% |
| Return on Assets (Trailing Twelve Months) | -24.68% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -15.97% |
| Return on Equity (Trailing Twelve Months) | -30.53% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -14.59% |
| Return on Investment (Trailing Twelve Months) | -26.93% |
| Return on Investment (5 Year) | -99,999.99% |